Accès ouvert
2026
other
OpenAlex
Utku Köse, Gözde Özkan Tükel, Ilhan Uysal, Erdem Sürücü et autres
This study aims to develop a personalised pharmacokinetic / pharmacodynamic model for 6-mercaptopurine (6-MP) used in the treatment of childhood acute lymphoblastic leukemia (ALL). The developed model considers both neutrophil count and white blood cells in the context of lifestyle-related inflammatory responses …
kz, tr
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Utku Köse, Gözde Özkan Tükel, İlhan Uysal, Erdem Sürücü et autres
This study aims to develop a personalised pharmacokinetic / pharmacodynamic model for 6-mercaptopurine (6-MP) used in the treatment of childhood acute lymphoblastic leukemia (ALL). The developed model considers both neutrophil count and white blood cells in the context of lifestyle-related inflammatory responses …
kz, tr
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Utku Köse, Gözde Özkan Tükel, İlhan Uysal, Erdem Sürücü et autres
This study aims to develop a personalised pharmacokinetic / pharmacodynamic model for 6-mercaptopurine (6-MP) used in the treatment of childhood acute lymphoblastic leukemia (ALL). The developed model considers both neutrophil count and white blood cells in the context of lifestyle-related inflammatory responses …
kz, tr
(code pays fourni par la source)
Accès ouvert
2026
other
OpenAlex
Utku Köse, Gözde Özkan Tükel, Ilhan Uysal, Erdem Sürücü et autres
This study aims to develop a personalised pharmacokinetic / pharmacodynamic model for 6-mercaptopurine (6-MP) used in the treatment of childhood acute lymphoblastic leukemia (ALL). The developed model considers both neutrophil count and white blood cells in the context of lifestyle-related inflammatory responses …
kz, tr
(code pays fourni par la source)
Accès ouvert
2025
other
OpenAlex
Utku Köse, Gözde Özkan Tükel, İlhan Uysal, Erdem Sürücü et autres
As illustrated in Figure 1, the 6-MP therapy optimisation model starts by considering lifestyle factors and patient-related traits (entry factors) as the input data for the model. In the second step, these data are integrated into a pharmacokinetics (PK) module, which can …
kz, tr
(code pays fourni par la source)
Accès ouvert
2025
other
OpenAlex
Utku Köse, Gözde Özkan Tükel, İlhan Uysal, Erdem Sürücü et autres
The developed model considers both neutrophil count and white blood cells in the context of lifestyle-related inflammatory responses (affected by nutrition, diet, and the vitamin D), genetic variations (e.g., TPMT), and also age-related pharmacokinetic values. In detail, the model is structured by …
kz, tr
(code pays fourni par la source)
Accès ouvert
2025
other
OpenAlex
Utku Köse, Gözde Özkan Tükel, İlhan Uysal, Erdem Sürücü et autres
Figure 2 shows that 6-TGN levels differ depending on TPMT genotype. Patients with low TPMT activity exhibit significantly higher 6-TGN accumulation, while those with high TPMT activity show lower levels. WBC counts declined rapidly during the first 4-6 weeks but stabilised in …
kz, tr
(code pays fourni par la source)
Accès ouvert
2025
other
OpenAlex
Utku Köse, Gözde Özkan Tükel, İlhan Uysal, Erdem Sürücü et autres
The simulation findings clearly demonstrate the impact of environmental factors on the haematopoietic system. Specifically, under the conditions defined in Scenario 3 (high vitamin D levels, adequate nutrition, and regular exercise), both WBC and ANC production are observed to be activated earlier …
kz, tr
(code pays fourni par la source)
Accès ouvert
2025
other
OpenAlex
Utku Köse, Gözde Özkan Tükel, İlhan Uysal, Erdem Sürücü et autres
Figure 2 shows that 6-TGN levels differ depending on TPMT genotype. Patients with low TPMT activity exhibit significantly higher 6-TGN accumulation, while those with high TPMT activity show lower levels. WBC counts declined rapidly during the first 4-6 weeks but stabilised in …
kz, tr
(code pays fourni par la source)
Accès ouvert
2025
other
OpenAlex
Utku Köse, Gözde Özkan Tükel, İlhan Uysal, Erdem Sürücü et autres
The runner_daily.py module was developed to examine the daily effects of 6-MP on haematological parameters and to develop a personalised chemotherapy management strategy. Using the module, the daily dose of 6-MP is optimised through a genetic algorithm-based approach, and the resulting changes …
kz, tr
(code pays fourni par la source)
Accès ouvert
2025
other
OpenAlex
Utku Köse, Gözde Özkan Tükel, İlhan Uysal, Erdem Sürücü et autres
This study aims to develop a personalised pharmacokinetic / pharmacodynamic model for 6-mercaptopurine (6-MP) used in the treatment of childhood acute lymphoblastic leukemia (ALL). The developed model considers both neutrophil count and white blood cells in the context of lifestyle-related inflammatory responses …
kz, tr
(code pays fourni par la source)
Accès ouvert
2025
other
OpenAlex
Utku Köse, Gözde Özkan Tükel, İlhan Uysal, Erdem Sürücü et autres
The developed model considers both neutrophil count and white blood cells in the context of lifestyle-related inflammatory responses (affected by nutrition, diet, and the vitamin D), genetic variations (e.g., TPMT), and also age-related pharmacokinetic values. In detail, the model is structured by …
kz, tr
(code pays fourni par la source)